For ovarian cancer (in both TCGA-OV and HD-OV), breast cancer (in TCGA-BRCA), and the remaining cancer types (TCGA-PANCAN*), biallelic (BA) mutations of BRCA1/2 (class H1a) were associated with significantly lower fdeam compared with tumors without alterations in the HR-genes (class H3). This evidence concerns the gene BRCA1 and ovarian carcinoma.